Shenzhen Bay Laboratory (Guangdong Laboratory of Life Information and Biomedicine) represents a major strategic initiative by Guangdong Province and Shenzhen to establish a Guangdong-Hong Kong-Macao international science and technology innovation center and a comprehensive national science center. It serves as a primary innovation hub in Shenzhen's endeavor to become a pilot demonstration zone of socialism with Chinese characteristics. The laboratory is permanently located in Guangming Science City and is planned for a total construction area of 400,000 square meters.
Shenzhen Bay Laboratory is committed to the world's science and technology frontier and people's life and health. It is closely aligned with the national strategic layout, guided by collaborative efforts to solve major scientific problems in life and health. The laboratory focuses on preventing, diagnosing, and treating major diseases such as tumors, metabolic disorders, cardiovascular diseases, neurodegenerative diseases, and infectious diseases. It is characterized by the integration of IT and BT, as well as interdisciplinary collaboration. Research on disease mechanisms, vital information, innovative drugs, and medical imaging will be conducted. The laboratory leverages its strengths in life sciences to jointly build the Guangdong-Hong Kong-Macao Greater Bay Area Collaborative Innovation Community and aims to become a world-class scientific and technological innovation hub.
Bayray Innovation Center is a pioneer in the research translation of the Shenzhen Bay laboratory. Leveraging the national strategic layout of the Guangdong-Hong Kong-Macao Greater Bay Area, the Center engages in in-depth cooperation with the world's leading enterprises, universities, and investment institutions. It bridges the gap between cutting-edge scientific discovery and commercialization in the realm of novel drug research and development. By building upon its core strengths in synthesis and pharmaceutical chemistry to connect basic research with drug development, the Center aims to transform emerging science and breakthrough technologies into differentiated therapies impacting the lives of patients globally. It also works to advance the biomedical ecosystem in South China and establish itself as a global leader in drug research and technology innovation.
Bayray Innovation Center currently has a team of over 90 employees, the majority of whom are scientific researchers. More than half of its employees have an overseas education and working background. Bayray's team is adept at transforming emerging science into therapies through the entire process from drug target screening to drug delivery. The core team management members are primarily from renowned pharmaceutical companies such as Pfizer, Abbott, Novartis, and Shinichi. All members boast over 20 years of experience in new drug research and development and high-level scientific research management, and they have led numerous innovative drug research and development projects. With a mission to transform cutting-edge science into innovative therapies, Bayray strives to advance the global healthcare industry.